AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7262795
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (application of Jellin ointment or cream alone, n = 24)
Trial: 7262795
Drug: Weekly interval
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly interval therapy (application of Jellin ointment or cream for 4 days followed by 3 days of the corresponding base, n = 21)
Trial: 7262795
Drug: Daily interval
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily interval therapy
Trial: 7262795
Drug: Interval therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interval therapy
Trial: 30845322
Drug: Typhoid conjugate
RxNorm normalized name: Typhoid conjugate vaccine (TCV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Typhoid conjugate vaccine campaign
Trial: 9923411
Drug: rhIL-11 (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIL-11 (both doses)
Trial: 776197
Drug: Subanaesthetic incremental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subanaesthetic incremental doses of Althesin
Trial: 776197
Drug: Single sedative
RxNorm normalized name: MedActive Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single sedative dose of diazepam
Trial: 30641027
Drug: Indacaterol/Glycopyrronium (IND/GLY)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indacaterol/Glycopyrronium (IND/GLY) 110/50 μg once daily for 14 days
Trial: 25593053
Drug: Transendocardial stem
RxNorm normalized name: stem bromelain
DrugBank: Stem bromelain (DB12249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transendocardial stem cell injection (TESI) using culture‐expanded mesenchymal stem cells (MSCs)
Trial: 19527481
Drug: Biphasic insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biphasic insulin aspart (BIAsp) three times a day (70/30 high-mix before breakfast and lunch, 30/70 before dinner)
Trial: 19527481
Drug: Biphasic insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biphasic insulin aspart (BIAsp) three times a day
Trial: 19527481
Drug: Biphasic human
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biphasic human insulin (BHI) 30/70 twice a day
Trial: 14993632
Drug: Multi-dose DEC
RxNorm normalized name: Zodryl DEC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-dose DEC (6 mg/kg) and Alb (400 mg) for seven days
Trial: 14993632
Drug: Re-treatment with
RxNorm normalized name: Re-Covr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Re-treatment with single-dose DEC/Alb 12 months after first treatment
Trial: 11207085
Drug: 3.4 g
RxNorm normalized name: psyllium 3.4 g oral wafer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.4 g of omega-3 fatty acids daily
Trial: 8422853
Drug: Carbamazepine 600
RxNorm normalized name: carbamazepine 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine 600 mg
Trial: 24417206
Drug: Carbamazepine 400
RxNorm normalized name: carbamazepine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine 400 mg
Trial: 17161535
Drug: Lamotrigine 300
RxNorm normalized name: lamotrigine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamotrigine 300 mg
Trial: 3009634
Drug: RRV-1 vaccine
RxNorm normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RRV-1 vaccine
Trial: 6143964
Drug: RIT 4237
RxNorm normalized name: measles virus vaccine live, attenuated Schwarz strain / mumps virus vaccine live, RIT-4385 strain / rubella virus vaccine live (Wistar RA 27-3 strain) Injection [Priorix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RIT 4237 vaccine
Trial: 15069129
Drug: Epidural steroid
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural steroid injection
Trial: 29858113
Drug: Tight-control treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tight-control treatment aiming at SDAI ≤ 3.3
Trial: 29858113
Drug: Tight-control treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tight-control treatment aiming at DAS28-CRP < 2.6
Trial: 27487966
Drug: Nurse-initiated antiviral
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nurse-initiated antiviral therapy with pegylated interferon and ribavirin
Trial: 27487966
Drug: Physician-initiated antiviral
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Physician-initiated antiviral therapy with pegylated interferon and ribavirin
Trial: 24759852
Drug: Family-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-based cognitive behavior therapy (FB-CBT) including exposure plus response prevention
Trial: 24759852
Drug: FB relaxation
RxNorm normalized name: FB-825
DrugBank: FB-825 (DB17598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FB relaxation treatment (FB-RT)
Trial: 23159875
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg oral mecamylamine
Trial: 17553503
Drug: Massaging with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massaging with dimethyl sulfoxide (DMSO) cream
Trial: 17553503
Drug: Massaging with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massaging with an indifferent cream
Trial: 12017395
Drug: Rofecoxib 50
RxNorm normalized name: rofecoxib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib 50 mg
Trial: 11560018
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of atenolol and enalapril maleate
Trial: 11560018
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of atenolol, enalapril maleate, and hydrochlorothiazide
Trial: 8167121
Drug: University of
RxNorm normalized name: ALCOHOL 75 mL in 100 mL TOPICAL GEL [University of Michigan]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: University of Wisconsin solution
Trial: 8167121
Drug: Buffered cold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buffered cold cardioplegic solution
Trial: 6449205
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g mezlocillin/oxacillin (20% solution) injected intramuscularly
Trial: 6449205
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g mezlocillin/oxacillin (25% aqueous solution) injected intramuscularly t.i.d. for about 7 days
Trial: 31641754
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of ivermectin, diethylcarbamazine, and albendazole (IDA)
Trial: 31641754
Drug: 3 annual
RxNorm normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 annual doses of ivermectin and albendazole (IA)
Trial: 31641754
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of IDA
Trial: 28125621
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group (viewing a video featuring individuals living in extreme poverty)
Trial: 21120562
Drug: 5 mCi
RxNorm normalized name: iobenguane I-131 15 MCI/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mCi Yttrium-90 plus 40 mg of triamcinolone hexacetonide (Y/TH Group)
Trial: 21120562
Drug: 15 mCi
RxNorm normalized name: iobenguane I-131 15 MCI/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mCi Samarium-153 hydroxyapatite plus 40 mg of triamcinolone hexacetonide (Sm/TH Group)
Trial: 21120562
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg triamcinolone hexacetonide alone (Control Group)
Trial: 19668094
Drug: Captain's Log
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captain's Log cognitive training software (8 weeks, weekly sessions)
Trial: 10048504
Drug: Irbesartan 75
RxNorm normalized name: irbesartan 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan 75 mg once daily (doubled at week 6 if seated diastolic blood pressure >= 90 mmHg)
Trial: 2923821
Drug: Ethanol (95%‐0.84
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (95%‐0.84 ml/kg)
Trial: 29033138
Drug: Escitalopram (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (20 mg daily) - overt group
Trial: 25528758
Drug: Second generation
RxNorm normalized name: Second generation cephalosporin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second generation antipsychotics
Trial: 20058592
Drug: Intradiscal methylene
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradiscal methylene blue (MB) injection
Trial: 17264356
Drug: Negative pressure
RxNorm normalized name: DRESSING,NEGATIVE PRESSURE WOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative pressure wound therapy (vacuum-assisted closure)
Trial: 3356049
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of epidural bupivacaine-fentanyl (initial dose of 5-7 ml, continuous infusion of 3 ml/h)
Trial: 3356049
Drug: Repeated injections
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated injections of epidural bupivacaine-fentanyl (initial dose ranged from 8-12 ml)
Trial: 29434529
Drug: High-protein diet
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-protein diet (≥2.2 g/kg/d)
Trial: 22192511
Drug: Pravastatin 40
RxNorm normalized name: pravastatin 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 40 mg/day
Trial: 18481712
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment within 1 month after operation
Trial: 18481712
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment within 2 weeks after attack
Trial: 14637261
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy + atorvastatin (10 mg/day), Group B
Trial: 14637261
Drug: Conventional therapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy, Group A
Trial: 14637261
Drug: Atorvastatin (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (in vitro, 0.1-10 micromol/l)
Trial: 10718567
Drug: Implicit learning
RxNorm normalized name: Empliciti
DrugBank: Elotuzumab (DB06317)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Implicit learning (concurrent secondary tone-counting task)
Trial: 8258205
Drug: Amoxicillin 40
RxNorm normalized name: amoxicillin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin 40 mg/kg/day for 10 days (Group I: one total dose of amoxicillin and two doses of placebo daily)
Trial: 8258205
Drug: Amoxicillin 40
RxNorm normalized name: amoxicillin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin 40 mg/kg/day for 10 days (Group II: three divided doses of amoxicillin daily)
Trial: 3896354
Drug: Masker treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Masker treatment
Trial: 3896354
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with no instrumental treatment
Trial: 3896354
Drug: Hearing aid
RxNorm normalized name: hearing aid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hearing aid or combination instrument treatment
Trial: 23131884
Drug: Acamprosate (2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acamprosate (2000 mg/d)
Trial: 10561343
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy
Trial: 26287955
Drug: Standard triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard triple therapy
Trial: 12426517
Drug: Nasal methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal methadone (10 mg)
Trial: 12426517
Drug: Intravenous methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous methadone (10 mg)
Trial: 12426517
Drug: Oral methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral methadone (10 mg)
Trial: 8765442
Drug: High-dose ondansetron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ondansetron
Trial: 8765442
Drug: Single-dose ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose ondansetron
Trial: 1834161
Drug: Ondansetron (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (8 mg loading dose; A: 4 mg i.v. + 4 mg orally; B: 8 mg i.v.), followed by oral treatment for 5 days (A: 6‐hourly; B: 8 mg 8‐hourly)
Trial: 6349653
Drug: Meclofenamate sodium
RxNorm normalized name: Meclofenamate Sodium
DrugBank: Meclofenamic acid (DB00939)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meclofenamate sodium (200 mg/day for 1 week, 250 mg/day for 2nd week, 300 mg/day for 3rd to 8th week)
Trial: 6349653
Drug: Indometacin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indometacin (100 mg/day for 1 week, 125 mg/day for 2nd week, 150 mg/day for 3rd to 8th week)
Trial: 30158029
Drug: 0.5% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine injection (20 ml) at port sites
Trial: 30158029
Drug: No bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No bupivacaine injection
Trial: 26871297
Drug: Extended-release guanfacine
RxNorm normalized name: guanfacine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release guanfacine hydrochloride (GXR)
Trial: 22830389
Drug: MTX 25
RxNorm normalized name: MTX
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MTX 25 mg once weekly
Trial: 22830389
Drug: MTX 10
RxNorm normalized name: MTX
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MTX 10 mg once weekly
Trial: 20832994
Drug: Nicorandil (bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil (bolus injection of 100 μg/kg, continuous injection of 60‐100 μg/kg/h for 5 days)
Trial: 17369799
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (20 g day(‐1) of creatine monohydrate for 21 days)
Trial: 16379507
Drug: risperidone (0.5-3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: risperidone (0.5-3.5 mg/day)
Trial: 10051720
Drug: Specific immunotherapy
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific immunotherapy (SIT) with HDM extract (Alavac, Bencard) for 2 years
Trial: 28482901
Drug: Daily listening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily listening to specially composed songs for 12 weeks
Trial: 28482901
Drug: Daily relaxation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily relaxation for 12 weeks
Trial: 23023407
Drug: 0.1% pranoprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% pranoprofen (PN) eye drops, 4 times daily for 4 weeks
Trial: 23023407
Drug: 0.1% fluorometholone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% fluorometholone (FL) eye drops, 4 times daily for 4 weeks
Trial: 21613025
Drug: Dentin desensitizer
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dentin desensitizer and ozone treatment
Trial: 19111473
Drug: Weekly infusional
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly infusional 5‐FU 2250 mg/m2 over 48 h plus bimonthly oxaliplatin 85 mg/m2
Trial: 19111473
Drug: Weekly infusional
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly infusional 5‐FU plus oxaliplatin
Trial: 16710073
Drug: Low-dose pioglitazone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose pioglitazone (7.5 mg/day)
Trial: 16710073
Drug: Standard-dose pioglitazone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose pioglitazone (15 mg/day)
Trial: 3315397
Drug: 1% amino
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% amino acid dialysis solution
Trial: 269880
Drug: Pluronic F‐127
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pluronic F‐127 plus sodium citrate gel
Trial: 269880
Drug: Pluronic F‐127
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pluronic F‐127 gel
Trial: 21207920
Drug: 0.4% stannous
RxNorm normalized name: Stanimax 0.4% Stannous Fluoride Dental Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4% stannous fluoride gel
Trial: 26028283
Drug: Fasting/exercise/saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting/exercise/saline infusion
Trial: 26028283
Drug: Fasting/rest/iv glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting/rest/iv glucose infusions
Trial: 19156856
Drug: No history
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No history of chemotherapy
Trial: 19156856
Drug: Future radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Future radiation therapy planned post study recruitment
Trial: 15119910
Drug: Electroconvulsive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroconvulsive therapy (ECT), administered 3 times weekly
Trial: 27302143
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate plus sodium hyaluronate (9 mg)
Trial: 27302143
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate plus saline solution
Trial: 29466159
Drug: Aspirin (81
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (81 mg daily)
Trial: 19036898
Drug: NOS inhibition
RxNorm normalized name: C1-inhibiting factor
DrugBank: Human C1-esterase inhibitor (DB06404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NOS inhibition (10 mM N(G)-nitro-l-arginine methyl ester)
Trial: 10912743
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no aspirin)
Trial: 17382603
Drug: Rifaximin 200
RxNorm normalized name: rifAXIMin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin 200 mg 3 times daily for 3 days
Trial: 17382603
Drug: Rifaximin-loperamide combination
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifaximin-loperamide combination therapy
Trial: 17382603
Drug: Loperamide (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loperamide (4 mg initially followed by 2 mg after each unformed stool)
Trial: 14711550
Drug: Transdermal hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal hormone therapy (50 microg/d of E(2) and 140-170 microg/d of norethisterone acetate; n = 12)
Trial: 14711550
Drug: Oral hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral hormone therapy (2 mg of E(2) and 1 mg of norethisterone acetate; n = 12)
Trial: 11290880
Drug: Donepezil (DPZ)
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Donepezil (DPZ) 5-10 mg/d
Trial: 11290880
Drug: Rivastigmine (Riv)
RxNorm normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rivastigmine (Riv) 1.5 to 12 mg/d
Trial: 8049645
Drug: Cytotoxic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytotoxic therapy
Trial: 2465391
Drug: PVP16B (cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PVP16B (cisplatin plus etoposide plus bleomycin) administered in three courses over 9 weeks
Trial: 2465391
Drug: PVP16B (cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PVP16B (cisplatin plus etoposide plus bleomycin) administered in four courses over 12 weeks
Trial: 15554757
Drug: Topiramate (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate (titrated from 25 mg/day to a maximum of 600 mg/day)
Trial: 11912568
Drug: Topiramate (not
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate (not specified dosage)
Trial: 9778280
Drug: Glycopyrrolate 2
RxNorm normalized name: glycopyrrolate 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate 2 mg twice daily
Trial: 7523607
Drug: Localized disease
RxNorm normalized name: RECTAL,LOCAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Localized disease treatment (MOPP plus radiation)
Trial: 3220232
Drug: Acetorphan (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetorphan (2.5 mg/kg intravenously at a constant rate in 20 min)